Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
2.580
-0.080 (-3.01%)
At close: Dec 5, 2025, 4:00 PM EST
2.628
+0.048 (1.84%)
After-hours: Dec 5, 2025, 7:47 PM EST
Clover Health Investments Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Clover Health Investments stock have an average target of 4.23, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 63.95% from the current stock price of 2.58.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for Clover Health Investments stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.1 → $3.7 | Strong Buy | Maintains | $4.1 → $3.7 | +43.41% | Nov 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.5 → $4.1 | Strong Buy | Maintains | $4.5 → $4.1 | +58.91% | Aug 7, 2025 |
| UBS | UBS | Hold Maintains $4.5 → $3 | Hold | Maintains | $4.5 → $3 | +16.28% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +74.42% | Mar 3, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +132.56% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
1.94B
from 1.37B
Increased by 41.68%
Revenue Next Year
2.67B
from 1.94B
Increased by 37.69%
EPS This Year
-0.18
from -0.09
EPS Next Year
-0.03
from -0.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.0B | 2.9B | ||||
| Avg | 1.9B | 2.7B | ||||
| Low | 1.9B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 46.4% | 47.2% | ||||
| Avg | 41.7% | 37.7% | ||||
| Low | 35.2% | 27.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | 0.02 | |||
| Avg | -0.18 | -0.03 | |||
| Low | -0.18 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.